Article ID Journal Published Year Pages File Type
10213309 International Journal of Cardiology 2018 27 Pages PDF
Abstract
Compared to aspirin, rivaroxaban in combination with aspirin is likely to be cost-effective in preventing recurrent cardiovascular events in patients with stable atherosclerotic vascular disease.
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Preview
Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective
Authors
, , , ,